spacer
home > ebr > Autumn 2012
PUBLICATIONS

European Biopharmaceutical Review

ebr
Autumn 2012

   
Text
PDF
BioBusiness, Finance & Communication
Incentivising R&D

Patent versus Patient

Nick Beckett of CMS Cameron McKenna examines the complex interface of intellectual property and competition law, and weighs up these very different approaches to stimulating innovation in the biotech sector.
 
view
download pdf
Spotlight

Open Innovation

Thomas Bombelles of the World Intellectual Property Organization presents the initiatives coordinated by the consortium WIPO Re:Search in their attempt to promote research into neglected tropical diseases through shared intellectual property.
 
view
download pdf
Identity Trust

Sign on the Digital Line

Being able to reliably identify a digital contact is essential to business in the current global market. Mollie Shields-Uehling of SAFE-BioPharma Association examines an industry-wide approach designed to build this trust.
 
view
download pdf
bullet
BioResearch and Innovation
Monoclonal Antibodies

Hitting the Target

Zhengbin (Bing) Yao of MedImmune takes a look at the advantages of mAb therapy to respiratory, infl ammatory and autoimmune (RIA) diseases, and reviews some key early mAb entrants into the RIA market.
 
view
download pdf
Targeted Cancer Therapeutics

Resisting Mutation, Restricting Resistance

William C Shakespeare of ARIAD Pharmaceuticals, Inc explores the mechanisms of resistance and next-generation agents in development for biomarker-driven, targeted non-small cell lung cancer therapeutics, several of which are designed specifically to target disease-resistant mutations.
 
view
download pdf
Biological Wound Care

A Topical Subject

Wound care is a growing business; competition is on the rise and differentiation will be the key to success. The future, argues Paul Titley of Aesica, lies in biologics, gene therapy and specific cell-based therapies for molecular and genomic deficiencies.
 
view
download pdf
bullet
Discovery Technology
MRI

A Secret Weapon

Recent developments in magnetic resonance imaging that have unlocked stronger field strengths and increased sensitivity. Ross McLennan at Brains Unlimited explores how this technology can enhance our understanding of the disease and aid target identification.
 
view
download pdf
Digital Pathology

Picture Perfect

Digital pathology has emerged as a core technology for drug discovery and the development of new tissue diagnostic tests. Peter Hamilton of PathXL Ltd examines just how this technology can offer improved efficiency, workflow and interoperability.
 
view
download pdf
Sample Management

A Store Point

High-quality samples are an invaluable asset for biomarker discovery and drug development. Kristina Robson of BioStorage Technologies illustrates how samples can be handled and stored with good storage practices to ensure their integrity is maintained for current and future research.
 
view
download pdf
Paperless Labs

In with the New

The demand for paperless labs to bring together isolated silos of information and establish new found efficiencies has never been greater. Susan Najjar of Thermo Fisher Scientific considers the factors to bear in mind when selecting a system.
 
view
download pdf
BioDevelopment
Drug Induced Liver Injury

Mindful Medical Monitoring

Akhil Kumar, Maxim Kosov, Marcelo Yantorno and Maxim Belotserkovsky at PSI CRO AG explore the complex subject of drug induced liver injury and the impact of false diagnoses on clinical trials.


 
view
download pdf
bullet
BioFormulation and Manufacturing
Biomanufacturing: Prophages

The Good, the Bad and the Ugly

When considering lysogenic bacteria as a host in biomanufacturing, it is essential to maintain a high degree of care during construction of the production process and ensure that well developed control tests and procedures are in place, as Marcin Los of Phage Consultants demonstrates.

 
view
download pdf
Getting Specific

Analytical Methods: Host Cell Proteins

Olaf Stamm, Mark Jostameling, Stephanie Graze and Simone Scotti of Charles River weigh up the benefits of generic and product-specific assays for the quantitative analysis of residual host cell proteins.



 
view
download pdf
Reinventing the Column

Analytical Methods: UHPLC

Existing analytical analysis solutions have proven inadequate for the new generation of complex protein therapeutics. Michael McGinley of Phenomenex Inc examines advances made by new UHPLC column technology that can stand up to the challenge.
 
view
download pdf
   
spacer


Published quarterly in
January, April,
July, and October

News and Press Releases

Non-invasive SONOFLOW | Flow Sensors and SONOFLOW | C Software: The user-friendly smart sensoring package for application in laboratory 4.0, R&D, and single-use production environments

With the influence of digitization and increasing needs for process monitoring, laboratory, R&D, and single-use production environments are changing rapidly. Networked laboratory devices with smart functions, automation concepts, and efficient interface solutions have altered laboratory workflows and stand for the new era of Lab 4.0. Therefore, a rising tide of the continuous availability of data requires an easy data handling and secure data logging.
More info >>

White Papers

How To Increase Efficiency, Customer Satisfaction and Reduce Cost

AC Labels

A customer of Riverside Medical had required a complex four-part 'piggy back' label. The labels needed to be specially constructed to facilitate removal in parts at various stages of its use for quality control traceability. This label needed to carry variable data elements of LOT numbers, batch numbers and product descriptions, and also a secondary gamma indicator label placed on each of its 4 sections to prove its sterility following sterilisation.
More info >>

Industry Events

BioTrinity 2020

28-29 April 2020, Etc Venues, London

BioTrinity is a long-running and highly regarded two day life sciences conference that takes place in Central London from 28-29 April. BioTrinity focuses on partnering, investment and collaboration and aims to inspire growth and create opportunities for all who attend. The core delegate mix includes early-stage and emerging biotech, medtech and digital health companies, big pharma executives and life sciences investors.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement